A Randomized Controlled Trial of Two Different Lengths of Nicotine Replacement Therapy for Smoking Cessation
Table 3
Quitting status using different outcome measures in the two groups at 6-month and 12-month followups, by intention to treat*.
Outcome measures
6 months
12 months
A1 () (%)
A2 () (%)
values
OR (95% CI)
A1 () (%)
A2 () (%)
values
OR (95% CI)
Main outcome
Self-reported 7-day point prevalence quit rate
78 (27.5)
76 (27.3)
0.97
1.0 (0.7–1.4)
60 (21.1)
59 (21.2)
0.98
1.0 (0.7–1.5)
Secondary outcomes
Biochemically validated (CO level in exhaled air) 7-day point prevalence quit rate
22 (7.7)
35 (12.6)
0.06
1.7 (0.9–3.0)
NA
NA
NA
NA
Self-reported 24-hour point prevalence quit rate
78 (27.5)
76 (27.3)
0.97
1.0 (0.7–1.4)
60 (21.2)
59 (21.2)
0.98
1.0 (0.7–1.5)
Self-reported continuous abstinence
71 (25.0)
69 (24.8)
0.96
1.0 (0.7–1.5)
52 (18.3)
51 (18.3)
0.99
1.0 (0.7–1.5)
Had not quit but had reduced smoking by at least 50% from the baseline level
49 (17.3)
50 (18.0)
0.48
1.1 (0.7–1.9)
39 (13.7)
44 (15.8)
0.48
1.2 (0.7–1.9)
Stopped smoking for at least 24 hours at some point prior to the interview
123 (47.9)
127 (53.1)
0.24
1.2 (0.9–1.8)
110 (38.7)
112 (40.3)
0.71
1.1 (0.8–1.5)
Note: OR: odds ratio; CI: confidence interval; NA: not applicable.
*Subjects who did not complete the intervention (withdrawn/could not be contacted) were considered not quitting. Those who had no validation were also considered as not quitting.
